China
Africa
Explore chapters and articles related to this topic
Treatment of Chronic Fatigue Syndrome
Published in Jay A. Goldstein, Chronic Fatigue Syndromes, 2020
The results of a peptide T trial in AIDS patients has recently been reported.44 There was no significant change in immune parameters, but there was an improvement in neuropsychiatric symptoms. Al-though peptide T was designed to block the action of gp120 at the CD4 receptor,45 which is also the VIP receptor, perhaps its mechanism of action is not immunologic but neuromodulatory. Peptide T may act in AIDS (and CFS) by being a VIP agonist. VIP may stimulate the secretion of IL-146 and is stored in nerve fibers with nitric oxide synthase in the outer, adventitial layers of large cerebral blood vessels.47 The drug is quite safe. It was used because peptide T and VIP can prevent gp120-induced neuronal cell death in vitro. gp 120 is the HIV surface molecule that binds to the CD4 receptor and has some sequence homology to VIP. It has been suggested that peptide T may have neurocognitive effects independent of its antiviral activity. A patient with CFS has had a good result using peptide T. We are planning a peptide T trial in CFS.
HIV and AIDS
Published in Peter R Wilson, Paul J Watson, Jennifer A Haythornthwaite, Troels S Jensen, Clinical Pain Management, 2008
A systematic review revealed that, on the basis of available evidence, mexilitine, capsaicin cream, and lidocaine gel are not efficacious in HIV peripheral neuropathic pain.28[I] There is also no efficacy for intranasal peptide T38[II] or memantidine.39[II]
Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018
Published in Expert Opinion on Therapeutic Patents, 2020
Yesim A Tahirovic, Sameshnee Pelly, Edgars Jecs, Eric J Miller, Savita K Sharma, Dennis C Liotta, Lawrence J Wilson
Teintze filed an application (WO2012047630) directed to N-alkyl and N-aryl substituted guanidine and bis-guanidine compounds for the treatment of bacterial infections, HIV and cancer, the promotion of stem cell mobilization, wound healing, hematopoiesis and skin rejuvenation [78]. The compounds bear some resemblance to the CXCR4 antagonist peptide T-140, which has five guanidine groups on the sidechains of arginine residues. There are 47 claims and 18 examples with data given for 40 discrete guanidine derivatives where the variation in the number of guanidine motifs ranges from one to eight on a single molecule (40, Figure 5). The bis and tris-phenylguanidine derivatives of spermidine exhibited the highest affinity for CXCR4 with an IC50 of 200 nM in competition binding assays with T-140.
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
Published in OncoImmunology, 2022
Michihisa Kono, Hiroki Komatsuda, Hidekiyo Yamaki, Takumi Kumai, Ryusuke Hayashi, Risa Wakisaka, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi, Yasuaki Harabuchi
PBMCs from HNSCC patients were co-cultured with FGFR1305-319 peptides in 96-well plates, as described previously.20 The PADRE peptide (capable of binding to all HLA-DR molecules) was co-cultured with PBMCs as a positive control. Briefly, PBMCs (1 × 105) were stimulated with peptides (10 µg/mL) for 2 cycles every 7 days, and IFN-γ production in the supernatants was measured using ELISA. Anti-HLA-DR Ab L243 (HB-55, ATCC) was applied to confirm that the IFN-γ production is mediated through HLA-DR/peptide/T cell receptor complex. All investigations were approved by the Institutional Ethics Committee of Asahikawa Medical University (#16217), and written informed consent was obtained from all participants.
Biologics for dengue prevention: up-to-date
Published in Expert Opinion on Biological Therapy, 2023
Adam T Waickman, Krista Newell, Timothy P Endy, Stephen J Thomas
Peptide vaccines are an alternative antigen delivery strategy specifically designed to elicited cytotoxic T cell responses. While this vaccine approach will not provide sterilizing immunity, the platform is designed to facilitate rapid clearance of DENV infected cells without risking the development of ADE. Emergex Vaccines has developed a synthetic peptide T cell vaccine – PepGNP-Dengue – in which peptides are presented by the most commonly occurring HLA alleles mounted on gold nanoparticles. PepGNP-Dengue – which is undergoing Phase I safety and immunogenicity evaluation (ClinicalTrials.gov Identifier: NCT04935801) – is administered by microneedle technologies, is stable at room temperature, and does not require an adjuvant.